Understand the source comparison
Comparison Table: Research Peptides for Stretch Mark Treatment
GHK-Cu (Copper Peptide) Upregulates collagen I/III synthesis via TGF-β signaling; modulates MMP-1/2 activity to reduce collagen degradation Microneedling (0.5–1.5mm depth) with 0.05–0.1% solution applied immediately post-treatment Moderate. Controlled trials s
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- GHK-Cu (Copper Peptide)
- Upregulates collagen I/III synthesis via TGF-β signaling; modulates MMP-1/2 activity to reduce collagen degradation
- Microneedling (0.5–1.5mm depth) with 0.05–0.1% solution applied immediately post-treatment
- Moderate. Controlled trials show 18–25% scar width reduction at 12 weeks with microneedling delivery
- 8–16 weeks for visible texture improvement; 20–24 weeks for measurable scar width reduction
- Strongest clinical evidence for dermal remodeling when delivered past stratum corneum; topical alone shows minimal efficacy
- TB-500 (Thymosin Beta-4 Fragment)
- Promotes fibroblast migration and angiogenesis through actin sequestration and VEGF upregulation
- Subcutaneous injection (0.25–0.5mL per cm of scar, weekly)
- Low. Extensive animal wound healing data; human striae-specific trials absent
- 12–20 weeks for improved vascularity and texture; effects on scar width less consistent than GHK-Cu
- Mechanistically sound for revascularization of atrophic scars; requires injection for bioavailability; evidence base weaker than copper peptides
- BPC-157 (Body Protection Compound)
- Accelerates fibroblast activity and collagen deposition via VEGF receptor and growth hormone signaling
- Subcutaneous injection adjacent to scar tissue (2–3x weekly for 8–12 weeks)
- Minimal. No peer-reviewed human trials for stretch marks; animal tendon repair data shows 40% faster healing
- 10–16 weeks for texture changes; scar width data unavailable
- Promising regenerative profile in connective tissue; human dermatology evidence lacking; off-label use based on extrapolation from musculoskeletal studies
- Palmitoyl Pentapeptide-4 (Matrixyl)
- Stimulates collagen synthesis through TGF-β receptor activation; smaller molecular weight than GHK-Cu
- Topical application (daily use in 2–5% concentration) or microneedling enhancement
- Weak. Manufacturer-funded studies show modest collagen density increase; no striae-specific controlled trials
- 16–24 weeks for subtle texture improvement; scar width effects negligible
- Marketed heavily in anti-aging serums; limited penetration without enhancement; safer profile but weaker efficacy than copper peptides or injectable options